Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Abstract

Purification and characterization of a dog cytochrome P450 isozyme belonging to the CYP2D subfamily and development of its antipeptide antibody.

A Nakamura, Y Yamamoto, T Tasaki, C Sugimoto, M Masuda, A Kazusaka and S Fujita
Drug Metabolism and Disposition November 1995, 23 (11) 1268-1273;
A Nakamura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y Yamamoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T Tasaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C Sugimoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Masuda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Kazusaka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Fujita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Species differences in the metabolism of bunitrolol (BTL) and propranolol (PL) in liver microsomes from rats and dogs were investigated. Hepatic microsomes from dogs lacked the ability to catalyze PL 7-hydroxylation, which is mediated by the CYP2D subfamily in rats. This suggested that dogs might lack the CYP2D subfamily; however, the antibody against cytochrome P450 (P450) BTL (CYP2D2) recognized a protein of approximately 49 kDa in hepatic microsomes from dogs, indicative of the presence of the CYP2D subfamily in dogs. The P450 purified from dog hepatic microsomes was designated P450 Canis familiaris (CF)1. It cross-reacted with the antibody against P450 BTL. The apparent molecular weight of the purified P450 CF1 was estimated to be 49 kDa. Its N-terminal amino acid sequence resembled the sequences of the members of the rat CYP2D subfamily and was the same as the sequences of the dog CYP2D subfamily, as deduced from the cDNA, except for the lack of four residues at the N-terminal. P450 CF1 could mediate metabolism of BTL and PL. P450 CF1, however, could not mediate PL 7-hydroxylation, which is almost exclusively mediated by CYP2D in rats. These findings indicate that P450 CF1 belongs to the CYP2D subfamily and that it differs functionally from the rat CYP2D subfamily. An antipeptide antibody against the synthetic peptide (DPTQPPRH), the sequence of which occurs in dog CYP2D at position 266-273 (S. Kirita et al., unpublished data), inhibited BTL 4-hydroxylase activity by 71% in dog hepatic microsomes at the substrate concentration of 0.01 M. This is further evidence that the CYP2D subfamily, in particular P450 CF1, is largely responsible for the oxidation of beta-blockers in dog hepatic microsomes.

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition
Vol. 23, Issue 11
1 Nov 1995
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Purification and characterization of a dog cytochrome P450 isozyme belonging to the CYP2D subfamily and development of its antipeptide antibody.
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract

Purification and characterization of a dog cytochrome P450 isozyme belonging to the CYP2D subfamily and development of its antipeptide antibody.

A Nakamura, Y Yamamoto, T Tasaki, C Sugimoto, M Masuda, A Kazusaka and S Fujita
Drug Metabolism and Disposition November 1, 1995, 23 (11) 1268-1273;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract

Purification and characterization of a dog cytochrome P450 isozyme belonging to the CYP2D subfamily and development of its antipeptide antibody.

A Nakamura, Y Yamamoto, T Tasaki, C Sugimoto, M Masuda, A Kazusaka and S Fujita
Drug Metabolism and Disposition November 1, 1995, 23 (11) 1268-1273;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics